ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CYTO Altamira Therapeutics Ltd

0.30
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Altamira Therapeutics Ltd NASDAQ:CYTO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.30 0.2921 0.2922 0 00:00:00

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

03/09/2024 2:01pm

GlobeNewswire Inc.


Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart


From Mar 2024 to Mar 2025

Click Here for more Altamira Therapeutics Charts.

Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City.  

Event: H.C. Wainwright Presentation On-Demand Date: September 09, 2024 Time: 7:00am ET Webcast: Link Registration: Link

Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company. To schedule a 1x1 investor meeting with Mr. Thomas Meyer, please send an email to meetings@hcwco.com. 

About Altamira Therapeutics Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/

1 Year Altamira Therapeutics Chart

1 Year Altamira Therapeutics Chart

1 Month Altamira Therapeutics Chart

1 Month Altamira Therapeutics Chart

Your Recent History

Delayed Upgrade Clock